Summary
Fibroblast growth factor (FGF) receptor 1 (FGFR1) is a potential therapeutic target for treatment of metastatic renal cell carcinoma (RCC). We investigated the preclinical activity of OM-RCA-01, a novel therapeutic humanized anti-FGFR1 antibody in RCC. OM-RCA-01 has been shown to inhibit in vitro kinase activity of FGFR1 and has high affinity (Kd of 1.59 nM). In human renal carcinoma Caki-1 FGFR1-expressing cells, OM-RCA-01 potently inhibited FGF-mediated signaling and proliferation. In vivo, the tumors in untreated mice or mice treated with non-specific IgG continued their aggressive growth to reach the size of 2,000 cm3, at which point the mice were killed. In contrast, treatment with OM-RCA-01 not only significant arrested further growth of the tumors (P < 0.01) but also demonstrated differences in tumor volume compared with vehicle already on Day 13. A similar anti-tumor activity of OM-RCA-01 was observed when the antibody was given in low (1 mg/kg) or high (10 mg/kg) doses (P = 0.917). In Matrigel assay, OM-RCA-01 significantly inhibited FGF-induced endothelial cell migration, capillary-like tubular structure and mature vessels formation. Administration of 10 mg/kg antibody for up to 35 days resulted in minimal body weight loss and no observations of gross toxicity were made. Collectively, the data obtained with OM-RCA-01 are consistent with potent inhibition of FGFR1-signaling, angiogenesis, and tumor growth. OM-RCA-01 is being developed clinically as an intravenous therapy for the treatment of clear cell RCC.
Similar content being viewed by others
References
Tsimafeyeu I, Aksel E (2010) Renal cell carcinoma in the Russian federation in 2008. Malign Tumours 1:1–4
Posadas EM, Figlin RA (2012) Systemic therapy in renal cell carcinoma: advancing paradigms. Oncology (Williston Park) 26(3):290–301
Tsimafeyeu I, Demidov L, Stepanova E et al (2011) Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma. Scand J Urol Nephrol 45:190–195
Rini BI, Atkins MB (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10(10):992–1000
Pal SK, Kortylewski M, Yu H, Figlin RA (2010) Breaking through a Plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers. Mol Cancer Ther 9(12):1–11
Tsimafeyeu I, Demidov L, Ta H, Stepanova E, Wynn N (2010) Fibroblast growth factor pathway in renal cell carcinoma. J Clin Oncol (Meeting Abstr) 28(15Suppl):4621
Brochet X, Lefranc MP, Giudicelli V (2008) IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 36:W503–W508
Thompson JD, Higgins DG, Gibson TJ, Clustal W (1994) Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties, and weight matrix choice. Nucleic Acids Res 22:4673–4680
Giudicelli V, Chaume D, Lefranc MP (2005) IMGT/GENE-DB : a comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res 33:D256–D261
Lefranc MP, Pommié C, Ruiz M et al (2003) IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol 27(1):55–77
Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147–1157
Acknowledgments
We would like to thank Maxwell Biotech, RVC and Skolkovo Funds for grant support.
Disclosures
IT, ES, and WL received research funding from OncoMax Ltd. EZ is a former employee of OncoMax Ltd.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tsimafeyeu, I., Zaveleva, E., Stepanova, E. et al. OM-RCA-01, a novel humanized monoclonal antibody targeting fibroblast growth factor receptor 1, in renal cell carcinoma model. Invest New Drugs 31, 1436–1443 (2013). https://doi.org/10.1007/s10637-013-0017-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-013-0017-x